1.The aberrant proliferation of certain lung cancer cells is primarily driven by NTRK1 rearrangements, and detection of NTRK1 translocation status can be performed.
2.It is a target for larotrectinib therapy.
3.This guides the selection of appropriate therapeutic strategies and personalized prognosis management.